You do not currently have access to this content.
Abstract:. In updated phase I clinical trial results, patients treated with zoldonrasib, a KRASG12D-selective inhibitor under study in non–small cell lung cancer, showed an objective response rate of ...
Cancer Res (2026) 86 (8_Supplement): CT184.
Abstract:. Under the Trump Administration’s proposed budget for fiscal year 2027, and if enacted, the NIH would receive $41.2 billion, down from $47.22 in fiscal year 2026, and NCI would receive ...
Cancer Res (2026) 86 (7_Supplement): 5811.
Cancer Immunol Res (2026) 14 (2_Supplement): B024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results